Publications by authors named "N ORSI"
The current troubled state of the global pathology workforce: a concise review.
Diagn Pathol
December 2024
The histopathology workforce is a cornerstone of cancer diagnostics and is essential to the delivery of cancer services and patient care. The workforce has been subject to significant pressures over recent years, and this review considers them in the UK and internationally. These pressures include declining pathologist numbers, the increasing age of the workforce, and greater workload volume and complexity.
View Article and Find Full Text PDFAT-rich interaction domain 1 () is a pivotal gene with a significant role in gastrointestinal tumors which encodes a protein referred to as BAF250a or SMARCF1, an integral component of the SWI/SNF (SWItch/sucrose non-fermentable) chromatin remodeling complex. This complex is instrumental in regulating gene expression by modifying the structure of chromatin to affect the accessibility of DNA. Mutations in have been identified in various gastrointestinal cancers, including colorectal, gastric, and pancreatic cancers.
View Article and Find Full Text PDFAchievement of Target Gain Larger than Unity in an Inertial Fusion Experiment.
Phys Rev Lett
February 2024
Article Synopsis
- * This experiment produced 2.05 MJ of laser energy, resulting in 3.1 MJ of total fusion yield, which exceeds the Lawson criterion for ignition, demonstrating a key milestone in fusion research.
- * The report details the advancements in target design, laser technology, and experimental methods that contributed to this historic achievement, validating over five decades of research in laboratory fusion.
Article Synopsis
- The study systematically reviewed the application of radiomics in imaging for ovarian lesions, analyzing data from 63 articles, with 33 found eligible.
- Most studies focused on lesion classification and treatment outcomes using various imaging techniques like CT and MRI, with a majority employing 3D segmentation.
- The findings suggest that radiomics could enhance clinical diagnostics for ovarian masses, though improvements in methodology and more extensive validations are necessary before widespread clinical use.
Results of recent clinical trials using the immune check point inhibitors (ICI) pembrolizumab or dostarlimab with/without lenvatinib has led to their approval for specific molecular subgroups of advanced recurrent endometrial cancer (EC). Herein, we summarise the clinical data leading to this first tissue-agnostic approval. As this novel therapy is not yet available in the United Kingdom standard care setting, we explore the strengths, weaknesses, opportunities, and threats (SWOT) of ICI treatment in EC.
View Article and Find Full Text PDF